Evogene Ltd.
Evogene Ltd. (EVGN) Revenue
Annual & quarterly revenue history · segment & region breakdown
EVGN · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsEvogene Ltd. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 30.91% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2011 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.00B | -30.91% |
| 2024-12-31 | $0.01B | +$0.00B | +87.02% |
| 2023-12-31 | $0.00B | +$0.00B | +78.03% |
| 2022-12-31 | $0.00B | +$0.00B | +80.11% |
| 2021-12-31 | $0.00B | -$0.00B | -10.58% |
| 2020-12-31 | $0.00B | +$0.00B | +38.11% |
| 2019-12-31 | $0.00B | -$0.00B | -56.90% |
| 2018-12-31 | $0.00B | -$0.00B | -48.33% |
| 2017-12-31 | $0.00B | -$0.00B | -48.30% |
| 2016-12-31 | $0.01B | -$0.00B | -41.23% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Evogene Ltd. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Evogene Ltd. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Evogene Ltd.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
EVGN revenue · 4 questionsEVGN's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 30.91% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Evogene Ltd. SEC filings · GAAP · Evogene Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026